CD44 antibodies bind to epitopes on the CD44 protein, which exists in multiple isoforms generated by alternative splicing (e.g., CD44 standard [CD44s] and variant isoforms [CD44v]) . Key functions modulated by CD44 antibodies include:
Inhibition of CD44-Hyaluronic Acid (HA) Interactions: Blocking HA binding disrupts tumor cell adhesion and metastasis .
Immune Activation: Antibodies like 44Mab-46-mG2a activate complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) .
Post-Translational Modification Targeting: Glycosylation states (e.g., HCELL glycoforms) influence antibody efficacy .
Esophageal Cancer: Anti-pan-CD44 monoclonal antibodies (5-mG2a and 44Mab-46-mG2a) suppressed xenograft tumor growth by 67–88% (CHO/CD44s cells) and 27–31% (KYSE770 cells) via CDC .
Colon Cancer: CD44v3–10-targeting antibodies reduced metastasis by 100% in murine models by blocking selectin interactions .
Antibody | Target Isoform | Cytotoxicity (%) | Model |
---|---|---|---|
5-mG2a | CD44s | 67 | CHO/CD44s xenograft |
44Mab-46-mG2a | CD44s | 88 | CHO/CD44s xenograft |
RG7356 | CD44s | N/A | Solid tumors |
Design: 65 patients with CD44-expressing solid tumors received RG7356 (100–2,250 mg biweekly/weekly) .
Results:
FcγR Blockade: Anti-CD44 antibodies (e.g., IM7) inhibit macrophage phagocytosis by occupying FcγR binding sites, reducing platelet clearance in immune thrombocytopenia .
Stem Cell Targeting: CD44 antibodies deplete cancer stem cells in breast and prostate cancers by disrupting HA-mediated survival signals .
Clone | Application | Species Reactivity | Vendor |
---|---|---|---|
#3578 | Western blot | Human | Cell Signaling |
C44Mab-46 | Flow cytometry, IHC | Human | MDPI |
ab157107 | IHC, Western blot | Human, Mouse | Abcam |
Western Blot: Detects CD44 at ~81 kDa (ab157107) and ~85 kDa (AF3660) .
Immunohistochemistry: Effective at 1:5,000 dilution in squamous cell carcinoma .
Isoform Variability: CD44v isoforms (e.g., CD44v5 in prostate cancer) correlate with better prognosis, complicating therapeutic targeting .
Biomarker Identification: CD44s overexpression in HA-rich tumors may predict RG7356 responsiveness .
Combination Therapies: Pairing CD44 antibodies with chemotherapy or checkpoint inhibitors enhances efficacy in preclinical models .
CD44 is involved in various biological processes, including:
CD44 is expressed in a wide range of tissues, including:
The primary functions of CD44 include:
CD44 mediates its effects through several mechanisms:
The expression and activity of CD44 are regulated by:
Mouse anti-human CD44 antibodies are widely used in research to study the expression and function of CD44 in human tissues. These antibodies are developed by immunizing mice with human CD44 protein, and they are used in various applications, including: